About the side effects of ADAMTS13 recombinant protease (trade name: Apadase α, English: Adzynma)

Adzynma (apadaseα) is a recombinant ADAMTS13 protease specifically indicated for the treatment of pediatric and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). cTTP is a rare genetic disease caused by mutations in the ADAMTS13 gene, resulting in lack or complete loss of ADAMTS13 protease activity in patients. The absence of this enzyme triggers the formation of abnormal blood clots in small blood vessels throughout the body, blocking blood flow to vital organs and causing organ damage. At the same time, excessive coagulation consumes platelets, leading to thrombocytopenia and increasing the risk of bleeding.

Patients may also develop purpura, which are purple spots that form from small bleeding spots under the skin. In addition, cTTP can accelerate the destruction of red blood cells and cause microangiopathic hemolytic anemia, which is manifested by symptoms such as fatigue, weakness, and shortness of breath. Adzynma helps restore normal coagulation function by supplementing the missing ADAMTS13 protease in patients, thereby reducing thrombosis and improving related symptoms.

AlthoughAdzynma is of great value in the treatment of cTTP, some adverse reactions may occur during use. The most common side effects include headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting, and the incidence of these reactions usually exceeds 5%. Headaches and migraines may interfere with patients' daily activities, while gastrointestinal symptoms such as diarrhea, abdominal pain, nausea, and vomiting may cause discomfort. Upper respiratory tract infections may manifest as cough, nasal congestion, or sore throat, while dizziness may increase the risk of falls, especially in older patients. Although most of these adverse reactions are mild to moderate, patients still need to be closely monitored during treatment and communicate with their doctors in a timely manner if discomfort occurs so that the treatment plan can be adjusted or appropriate symptomatic treatment can be taken.

Overall,Adzynma provides an important alternative treatment option for patients with cTTP, which can effectively improve coagulation function and reduce the risk of disease flare-ups. However, doctors should weigh their efficacy against potential adverse reactions when prescribing to ensure that patients receive the best therapeutic effect and safety.

Reference link:https://www.drugs.com/adzynma.html